Tue May 20 19:10:00 UTC 2025: **Summary:**
The Trump administration, through the FDA, is changing its approach to COVID-19 vaccine approvals. Seasonal boosters will be primarily aimed at seniors and high-risk individuals, pending further data on the benefits for healthier individuals. This shift raises concerns about accessibility and insurance coverage for those outside the priority groups and has drawn criticism from pediatricians and some vaccine experts who fear it will limit options and create confusion. The new policy, spearheaded by FDA commissioner Martin Markary and shaped by Health Secretary Robert F. Kennedy Jr.’s skepticism towards universal COVID-19 vaccination, prioritizes rigorous clinical trials for broader vaccine approval in healthy populations, marking a departure from the previous “one-size-fits-all” approach.
**News Article:**
**FDA to Limit COVID-19 Booster Access to High-Risk Groups, Citing Need for More Data**
**WASHINGTON (AP) —** The Trump administration announced Tuesday a significant shift in its COVID-19 vaccination strategy, limiting access to seasonal booster shots primarily to seniors and individuals with high-risk health conditions. The move comes as the Food and Drug Administration (FDA) calls for more extensive data on the benefits of boosters for the general population.
FDA Commissioner Martin Markary, speaking alongside President Trump in Washington, explained the new framework, which will prioritize those 65 and older and younger individuals with underlying health problems for streamlined access to updated COVID-19 vaccines. The FDA is urging vaccine manufacturers to conduct large, lengthy clinical trials to assess the efficacy of tweaked vaccines for healthier individuals before granting broader approval.
“For many Americans, we simply do not know if they should be getting the seventh, eighth, or tenth COVID-19 booster,” said Dr. Vinay Prasad, a recent appointee to the FDA. He emphasized the new approach as a compromise that ensures vaccinations for high-risk groups while gathering more data on the benefits for healthier individuals.
The policy shift, a culmination of scrutiny under Health Secretary Robert F. Kennedy Jr., is already drawing criticism. Concerns have been raised about potential confusion and access issues for those who may desire a fall COVID-19 shot but don’t fit the high-risk criteria. Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, questioned how risk assessment would be determined and warned the policy could make vaccines less insurable and available. The American Academy of Pediatrics expressed concerns that the new approach will limit options for parents who want to protect their children.
Pfizer and Moderna, the makers of the most widely used COVID-19 vaccines, said they would continue to work with the agency.
The FDA’s decision marks a departure from the previous approach of approving updated COVID-19 shots as long as they demonstrated similar immune protection to previous versions. The new guidance appears to align the U.S. with practices in some European countries that recommend boosters based on age, risk, and other factors.
The FDA’s decision comes ahead of a scheduled meeting of its outside vaccine experts, raising questions about the future of federal vaccine policy.
Copyright 2025 The Associated Press. All Rights Reserved.
First Piper 